Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG318 in Refractory Systemic Lupus Erythematosus
NCT07328581Phase 2Recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ICG318 in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by iCell Gene Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
ICG318
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07328581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328581.